Ironwood Pharmaceuticals (IRWD) Current Deferred Revenue (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Current Deferred Revenue across 15 years of filings, most recently posting $1.3 million for Q2 2026.

• In Q2 2026, Current Deferred Revenue rose 28.22% year-over-year to $1.3 million; the TTM figure through Jun 2026 stood at $1.3 million (up 28.22% YoY), while the FY2025 annual figure was $1.1 million, down 45.52% from the prior year.
• Current Deferred Revenue came in at $1.3 million for Q2 2026 at Ironwood Pharmaceuticals, down from $1.5 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $2.6 million in Q4 2023 to a low of $978000.0 in Q2 2025.
• Average Current Deferred Revenue over 4 years is $1.5 million, with a median of $1.4 million recorded in 2026.
• Year-over-year, Current Deferred Revenue sank 45.52% in 2025 and gained 28.22% in 2026.
• Over 4 years, Current Deferred Revenue stood at $2.6 million in 2023, then declined by 22.44% to $2.0 million in 2024, then plunged by 45.52% to $1.1 million in 2025, then gained by 13.28% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $1.3 million in Q2 2026, $1.5 million in Q1 2026, and $1.1 million in Q4 2025.